Citrini Research said that AI-accelerated drug discovery could support growth in the life sciences industry and named Charles River Laboratories and Revvity as potential beneficiaries after testing Anthropic’s Claude Science. According to Odaily, faster AI-driven design of drug candidates may increase demand for experimental validation, creating opportunities for companies that provide drug testing, laboratory equipment and research and development services. Charles River is a drug-testing service provider, while Revvity supplies research instruments and software; Citrini described Revvity as computing infrastructure for biotechnology research and development.